Literature DB >> 20453884

Hdm2 negatively regulates telomerase activity by functioning as an E3 ligase of hTERT.

W Oh1, E-W Lee, D Lee, M-R Yang, A Ko, C-H Yoon, H-W Lee, Y-S Bae, C Y Choi, J Song.   

Abstract

In this study, we identified posttranslational regulation of human telomerase reverse-transcriptase (hTERT) by the E3 ligase Hdm2. The telomerase activity generated by exogenous hTERT in U2OS cells was reduced on adriamycin treatment. The overexpressed levels of hTERT were also decreased under the same conditions. These processes were reversed by treatment with a proteasome inhibitor or depletion of Hdm2. Furthermore, intrinsic telomerase activity was increased in HCT116 cells with ablation of Hdm2. Immunoprecipitation analyses showed that hTERT and Hdm2 bound to each other in multiple domains. Ubiquitination analyses showed that Hdm2 could polyubiquitinate hTERT principally at the N-terminus, which was further degraded in a proteasome-dependent manner. An hTERT mutant with all five lysine residues at the N-terminus of hTERT that mutated to arginine became resistant to Hdm2-mediated ubiquitination and degradation. In U2OS cells, depletion of Hdm2 or addition of the Hdm2-resistant hTERT mutant strengthened the cellular protective effects against apoptosis. Similar results were obtained with the Hdm2-stable H1299 cell line. These observations indicate that Hdm2 is an E3 ligase of hTERT.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20453884     DOI: 10.1038/onc.2010.160

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  14 in total

1.  Tandem affinity purification of AtTERT reveals putative interaction partners of plant telomerase in vivo.

Authors:  Jana Majerská; Petra Procházková Schrumpfová; Ladislav Dokládal; Šárka Schořová; Karel Stejskal; Michal Obořil; David Honys; Lucie Kozáková; Pavla Sováková Polanská; Eva Sýkorová
Journal:  Protoplasma       Date:  2016-11-16       Impact factor: 3.356

Review 2.  Towards an understanding of regulating Cajal body activity by protein modification.

Authors:  Michael D Hebert; Aaron R Poole
Journal:  RNA Biol       Date:  2016-10-07       Impact factor: 4.652

3.  Characterization of cancer-associated missense mutations in MDM2.

Authors:  Krishna M Chauhan; Gopalakrishnan Ramakrishnan; Madhusudhan Kollareddy; Luis A Martinez
Journal:  Mol Cell Oncol       Date:  2015-12-10

4.  Polo-like Kinase 1 (Plk1) Up-regulates Telomerase Activity by Affecting Human Telomerase Reverse Transcriptase (hTERT) Stability.

Authors:  Yan Huang; Liping Sun; Ningning Liu; Qian Wei; Liangzhen Jiang; Xiaomei Tong; Xin Ye
Journal:  J Biol Chem       Date:  2015-06-12       Impact factor: 5.157

5.  The Many Faces of MDM2 Binding Partners.

Authors:  Maurisa F Riley; Guillermina Lozano
Journal:  Genes Cancer       Date:  2012-03

6.  Role for telomerase in Listeria monocytogenes infection.

Authors:  Ascel Samba-Louaka; Fabrizia Stavru; Pascale Cossart
Journal:  Infect Immun       Date:  2012-09-24       Impact factor: 3.441

7.  Dyrk2-associated EDD-DDB1-VprBP E3 ligase inhibits telomerase by TERT degradation.

Authors:  Hae-Yun Jung; Xin Wang; Sohee Jun; Jae-Il Park
Journal:  J Biol Chem       Date:  2013-01-28       Impact factor: 5.157

8.  Neuropilin-2 expression is inhibited by secreted Wnt antagonists and its down-regulation is associated with reduced tumor growth and metastasis in osteosarcoma.

Authors:  Tao Ji; Yi Guo; Kapjun Kim; Peter McQueen; Samia Ghaffar; Alexander Christ; Carol Lin; Ramez Eskander; Xiaolin Zi; Bang H Hoang
Journal:  Mol Cancer       Date:  2015-04-17       Impact factor: 27.401

Review 9.  Clinical implications of antitelomeric drugs with respect to the nontelomeric functions of telomerase in cancer.

Authors:  Jae-Il Roh; Young Hoon Sung; Han-Woong Lee
Journal:  Onco Targets Ther       Date:  2013-08-26       Impact factor: 4.147

10.  Chromatin structure in telomere dynamics.

Authors:  Alessandra Galati; Emanuela Micheli; Stefano Cacchione
Journal:  Front Oncol       Date:  2013-03-07       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.